This study is accepting new patients by invitation only

Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children

Description

Open-label, follow-up study for subjects who completed the EPITOPE study.

EPITOPE Open-label Extension Study to Evaluate the Long-term Clinical Benefit and Safety of DBV712 in Peanut-Allergic Children

Peanut Allergy, EPIT, Epicutaneous, Immunotherapy, Viaskin, Peanut Hypersensitivity, DBV712 250 mcg, DBV712 250mcg

Open to people ages 2-5

- completion of the EPITOPE study

Generalized dermatologic disease (for example, active atopic dermatitis, uncontrolled generalized active eczema, ichthyosis vulgaris) extending widely on the skin and especially on the back or arms with no intact zones to apply the Viaskin patches.
Diagnosis of asthma that evolved to severe, unstable or uncontrolled asthma